LIVA-HEALTHCARE
Liva Healthcare (“Liva”), a European market leader in scalable digital health coaching, has secured a new funding round of EUR 24.5 million, led by Verlinvest, the go-to investor for mission-driven entrepreneurs and category-defining global consumer brands. The investment will enable Liva to strengthen its position as a European leader in digital health and lifestyle coaching for chronic disease prevention and management.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210105005831/en/
Liva is a health tech company headquartered in Copenhagen and London with the mission to improve the lives of people at risk of, or living with, chronic conditions such as Type 2 diabetes, obesity, and heart diseases by driving positive behavioural change. Liva blends scalable health coaching focused on personal human relationships with an intuitive and user-friendly interface. Liva was founded in 2015 by the team behind independent health information portal NetDoctor.com.
The on-going Covid-19 pandemic has led to a significant shift in acceptance of remote healthcare by European consumers. This shift in acceptance and the subsequent patient behaviour has given Liva a significant increase in interest from public healthcare providers and life science companies in 2020.
Liva is used by clients such as Novo Nordisk, AXA Health, Amgen, City of Copenhagen, Bupa Australia and several other key players in public healthcare, insurance and life science industries globally. Liva is also a partner to NHS England on its world-leading National Diabetes Prevention Programme. Liva is currently operational in Britain, Australia, Ireland, Holland, Belgium, Denmark, Sweden, and Finland with operations currently being setup in Germany and Switzerland.
“This new funding, from one of Europe’s strongest purpose-led, consumer growth investors, will substantially accelerate our expansion in core European markets,” says André Sode, CEO of Liva Healthcare. “COVID-19 has demonstrated how effective remote digital health solutions can be. With healthcare providers around the world looking for scalable solutions to combat the rise in diabetes and obesity, we are ideally placed to support and have experienced a significant increase in interest as a result.”
“This investment represents a major new entry into digital health for Verlinvest, where technology is fuelling consumer revolutions,” says Simone Sallustio, Executive Director at Verlinvest. “Digital healthcare has been vital in getting treatment to patients during the pandemic and this trend will continue as effective virtual programmes give people more flexible healthcare options. Liva’s advanced technology and proven clinical outcomes set it apart from its competitors. In this exciting and rapidly evolving space, Liva’s experience and established partnerships represent a strategic choice for Verlinvest.”
About Liva Healthcare:
Liva Healthcare is a leading provider of scalable digital health coaching, delivering human-centric coaching through an advanced app to help people prevent and manage obesity, prediabetes, type 2 diabetes and cardiovascular diseases.
For more information: livahealthcare.com , LinkedIn and Twitter .
About Verlinvest:
Verlinvest is a privately-owned family investment company based in Brussels with offices in New York, London, and Singapore.
For more information: www.verlinvest.com and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210105005831/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bloom Announces Early 2026 UK Launch, Expanding into Europe with New Garden Pharma as Exclusive Manufacturer24.6.2025 07:05:00 CEST | Press release
The Bloom Brand, a recognized U.S. leader in cannabis vape, is making its international debut in the United Kingdom through an exclusive partnership with New Garden Pharma, a leading European EU-GMP cannabis operator. Together, the two companies will launch Bloom’s award-winning Classic and Live vape collections in the UK in Q1 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250623573625/en/ This marks Bloom’s first international market expansion, as the company continues its global growth strategy with additional EU markets in development for 2026 and beyond. UK patients will gain access to Bloom’s superior formulations and proprietary hardware systems. For more than a decade, Bloom has built its reputation on delivering terpene-rich, flavor-forward strains paired with reliable technology. The brand has an established and leading presence across leading U.S. markets including California, Illinois, Florida, Michigan, Mi
ACI Worldwide Expands Technology Partnership Ecosystem to Power ACI Connetic24.6.2025 07:00:00 CEST | Press release
ACI’s unified cloud-based payments platform to boost operational resiliency and support increasing non-functional requirements of modern payment systems ACI Worldwide (NASDAQ:ACIW), an original innovator in global payments technology, has expanded its global technology partnership ecosystem to help financial institutions across the globe increase operational resiliency and address evolving regulatory requirements to safeguard the stability of the financial system. Building on strategic partnerships with Microsoft, Red Hat and IBM, ACI is collaborating with MongoDB, a document-oriented NoSQL database, and open source technology NATS from Synadia Communications for the reference architecture of ACI Connetic, ACI’s unified, cloud-native payments platform. These partnerships help extend ACI Connetic far beyond a traditional payments hub, delivering robust, highly functional payment engines to support financial institutions in meeting growingly stringent non-functional requirements and incr
Industrial 3-axis accelerometer has high offset stability24.6.2025 04:00:00 CEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has introduced a 3-axis accelerometer for the industrial market that combines high offset stability over temperature and time, good linearity, low noise density, and excellent robustness. The SCA3400-D01 XYZ accelerometer is meant for use in industrial applications such as structural health monitoring (SHM), machine control, inertial measurement units, and construction tools and systems. This product will be exhibited at Sensors Converge 2025 to be held at the Santa Clara Convention Center (Booth #716), California from 24 to 26 June 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250623994075/en/ [Murata Manufacturing Co., Ltd.] Industrial 3-axis accelerometer The offset stability of an accelerometer refers to the consistency of its output when at rest, but subject to varying temperatures or the effects of aging. Ideally, this output should be zero, but i
Grid Dynamics Announces AI-Powered Engagement Model Enabling Accelerated Business Transformation for Fortune 1000 Enterprises23.6.2025 15:15:00 CEST | Press release
Key Takeaways: Grid Dynamics introduces an AI-powered engagement model for software delivery. This engagement model expands Grid Dynamics’ offerings by providing a fundamentally new way of delivering value—enabling clients to achieve superior outcomes by providing the next level of agility, quality, and accelerated time-to-market. The model is based on the Grid Dynamics AI-Native Development Framework (GAIN Development Framework)—a combination of proprietary processes, human capital, and an AI-Enabled Development Platform. This framework is designed specifically to support the scale and complexity of Fortune 1000 enterprises. Based on internal benchmarks, we expect this model to accelerate project delivery by achieving over 30% productivity improvements. Progressive credit-based pricing directly tied to performance and value is the basis of the new engagement model. Grid Dynamics Holdings, Inc. (Nasdaq: GDYN) (Grid Dynamics)—a prominent technology consulting and digital services provid
Live Biotherapeutics at a Crossroad: Novotech White Paper Outlines Opportunities and Early-Stage Challenges23.6.2025 14:05:00 CEST | Press release
As Live Biotherapeutic Products (LBPs) begin to transition from frontier science to clinical reality, Novotech, a leading global CRO and scientific advisory partner has published a new white paper examining the opportunities and challenges shaping this fast-evolving landscape of therapeutic class. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250623205345/en/ LBPs, which harness live microorganisms to restore or modulate human health, are being explored across a growing range of indications, from gastrointestinal and metabolic disorders to CNS and oncology. FDA approvals of Rebyota™ and Vowst™ have validated the category but for most biotech sponsors, the journey remains uncertain. According to Novotech’s analysis, over 90% of LBP assets are still in early development stages, and nearly one-third of all trials from 2020 to 2025 have been withdrawn or suspended due to regulatory, manufacturing, or design complexities. Highli
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom